FDA's Biosimilar Labeling Vision Stirs Up Discord
Drugmakers, consumer groups and patient advocates remain sharply divided over U.S. Food and Drug Administration proposals for the labeling of biosimilars, newly released correspondence shows....To view the full article, register now.
Already a subscriber? Click here to view full article